Leishmaniasis continues to be a major health problem in 4 eco-epidemiological regions of the world: the Americas, East Africa, North Africa and West and South-East Asia. This report on global leishmaniasis surveillance follows those published in 2016–2022. Six indicators of leishmaniasis are publicly available from the Global Health Observatory (GHO). In addition to the GHO, country profiles with up to 30 indicators are published, with detailed data received from 45 Member States.
The aims of this report are to update the description of the GHO leishmaniasis indicators reported by Member States to WHO up to 2022, to describe specific indicators of gender and age distribution, relapse, treatment, selected outbreaks, visceral leishmaniasis (VL) case fatality rates (CFRs), rates of co-infection with HIV for VL and the burden of post-kala-azar dermal leishmaniasis (PKDL). The report also contains a brief section on the kala-azar Elimination Programme in South-East Asia and adverse events after administration of antileishmanial drugs.
BT - Weekly Epidemiological Record IS - 98 LA - Eng N2 -Leishmaniasis continues to be a major health problem in 4 eco-epidemiological regions of the world: the Americas, East Africa, North Africa and West and South-East Asia. This report on global leishmaniasis surveillance follows those published in 2016–2022. Six indicators of leishmaniasis are publicly available from the Global Health Observatory (GHO). In addition to the GHO, country profiles with up to 30 indicators are published, with detailed data received from 45 Member States.
The aims of this report are to update the description of the GHO leishmaniasis indicators reported by Member States to WHO up to 2022, to describe specific indicators of gender and age distribution, relapse, treatment, selected outbreaks, visceral leishmaniasis (VL) case fatality rates (CFRs), rates of co-infection with HIV for VL and the burden of post-kala-azar dermal leishmaniasis (PKDL). The report also contains a brief section on the kala-azar Elimination Programme in South-East Asia and adverse events after administration of antileishmanial drugs.
PB - World Health Organization PY - 2023 SP - 471 EP - 488 T2 - Weekly Epidemiological Record TI - Weekly epidemiological record - Global leishmaniasis surveillance, 2022: assessing trends over the past 10 years UR - https://iris.who.int/bitstream/handle/10665/373227/WER9840-eng-fre.pdf?sequence=1&isAllowed=y VL - 40 ER -